CHRS
Price:
$1.24
Market Cap:
$142.86M
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biolo...[Read more]
Industry
Biotechnology
IPO Date
2014-11-06
Stock Exchange
NASDAQ
Ticker
CHRS
According to Coherus BioSciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.26. This represents a change of 104.08% compared to the average of -1.60 of the last 4 quarters.
The mean historical PE Ratio of Coherus BioSciences, Inc. over the last ten years is -0.32. The current -3.26 PE Ratio has changed 102.72% with respect to the historical average. Over the past ten years (40 quarters), CHRS's PE Ratio was at its highest in in the December 2020 quarter at 32.33. The PE Ratio was at its lowest in in the September 2014 quarter at -12.84.
Average
-0.32
Median
-1.92
Minimum
-9.27
Maximum
13.97
Discovering the peaks and valleys of Coherus BioSciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 148.97%
Maximum Annual PE Ratio = 13.97
Minimum Annual Increase = -596.90%
Minimum Annual PE Ratio = -9.27
Year | PE Ratio | Change |
---|---|---|
2023 | -1.32 | -29.98% |
2022 | -1.88 | -52.12% |
2021 | -3.93 | -141.89% |
2020 | 9.39 | -32.80% |
2019 | 13.97 | -596.90% |
2018 | -2.81 | 43.16% |
2017 | -1.96 | -78.81% |
2016 | -9.27 | 142.70% |
2015 | -3.82 | 148.97% |
2014 | -1.53 | -63.94% |
The current PE Ratio of Coherus BioSciences, Inc. (CHRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.38
5-year avg
3.24
10-year avg
-0.32
Coherus BioSciences, Inc.’s PE Ratio is less than Assembly Biosciences, Inc. (-2.10), less than Spero Therapeutics, Inc. (4.06), less than Achilles Therapeutics plc (-0.45), less than Instil Bio, Inc. (-0.78), less than Neoleukin Therapeutics, Inc. (-0.98), less than NextCure, Inc. (-0.65), less than Nuvation Bio Inc. (-1.34), less than CytomX Therapeutics, Inc. (9.19), less than Bolt Biotherapeutics, Inc. (-0.37), greater than Gracell Biotechnologies Inc. (-12.26),
Company | PE Ratio | Market cap |
---|---|---|
-2.10 | $107.81M | |
4.06 | $71.07M | |
-0.45 | $29.58M | |
-0.78 | $92.68M | |
-0.98 | $8.20M | |
-0.65 | $39.73M | |
-1.34 | $692.60M | |
9.19 | $93.74M | |
-0.37 | $24.78M | |
-12.26 | $989.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Coherus BioSciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Coherus BioSciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Coherus BioSciences, Inc.'s PE Ratio?
How is the PE Ratio calculated for Coherus BioSciences, Inc. (CHRS)?
What is the highest PE Ratio for Coherus BioSciences, Inc. (CHRS)?
What is the 3-year average PE Ratio for Coherus BioSciences, Inc. (CHRS)?
What is the 5-year average PE Ratio for Coherus BioSciences, Inc. (CHRS)?
How does the current PE Ratio for Coherus BioSciences, Inc. (CHRS) compare to its historical average?